These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 6662582)

  • 41. [Study of the effectiveness of vaccination against measles with and areactogenic vaccine].
    Boĭchuk LM; Kozlova NA; Smorodinova IP; Petrova TN; Desiatova SA
    Tr Leningr Nauchnoissled Inst Epidemiol Mikrobiol; 1973; 42():96-101. PubMed ID: 4808390
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical and serological studies on CAM-70 live attenuated measles vaccine: an 18-year survey at a pediatric clinic in Japan.
    Ozaki T; Matsui Y; Kajita Y; Nishimura N
    Vaccine; 2002 Jun; 20(19-20):2618-22. PubMed ID: 12057621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA; Harry TO
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measles infection following immunization: a report on forty-nine cases in Lagos, NIgeria.
    Williams GA
    Afr J Med Sci; 1971 Apr; 2(2):159-63. PubMed ID: 5111615
    [No Abstract]   [Full Text] [Related]  

  • 45. Studies on the combined use of killed and live measles vaccines. II. Advantages of the inhalation method.
    Okuno Y; Ueda S; Hosai H; Kitawaki T; Nakamura K; Chiang TP; Okabe S; Onaka M; Toyoshima K
    Biken J; 1965 Jun; 8(2):81-5. PubMed ID: 5837767
    [No Abstract]   [Full Text] [Related]  

  • 46. [Atypical measles with hepatic involvement].
    Riaño Galán I; Alonso Villa MJ; Cimadevilla Suárez R; Martínez Gutiérrez A
    An Esp Pediatr; 1992 May; 36(5):399-400. PubMed ID: 1616204
    [No Abstract]   [Full Text] [Related]  

  • 47. Panel on immunizations.
    Fulginiti VA; Nelson JD; McCracken GH
    Pediatr Infect Dis; 1983; 2(3 Suppl):S64-9. PubMed ID: 6866802
    [No Abstract]   [Full Text] [Related]  

  • 48. [Seroepidemiology of measles in 1428 people from a copper mine of Chengde City].
    Hao YW
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Oct; 6(5):289-91. PubMed ID: 3836746
    [No Abstract]   [Full Text] [Related]  

  • 49. [Duration of the immunity of attenuated measles vaccine. IV. Result of a 9-year observation following primary inoculation].
    Zhonghua Yi Xue Za Zhi; 1983 Jul; 63(7):423-5. PubMed ID: 6416645
    [No Abstract]   [Full Text] [Related]  

  • 50. [Immunoprophylaxis of measles].
    Barabash MA
    Feldsher Akush; 1980; 45(11):7-9. PubMed ID: 6450689
    [No Abstract]   [Full Text] [Related]  

  • 51. Measles vaccination of macaques by dry powder inhalation.
    de Swart RL; LiCalsi C; Quirk AV; van Amerongen G; Nodelman V; Alcock R; Yüksel S; Ward GH; Hardy JG; Vos H; Witham CL; Grainger CI; Kuiken T; Greenspan BJ; Gard TG; Osterhaus AD
    Vaccine; 2007 Jan; 25(7):1183-90. PubMed ID: 17084489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimum age of measles immunization--maternal and transplacentally transmitted measles antibodies in infancy.
    Mohan M; Mehta PK; Sehgal S; Prabhakar AK; Bhargava SK
    Indian Pediatr; 1981 Sep; 18(9):631-5. PubMed ID: 7319611
    [No Abstract]   [Full Text] [Related]  

  • 53. Measles antibody in the children in Ubon Ratchathani province.
    Saipan P; Jiwapaisarnpong T; Pattanadilok S; Loyha Y; Janggajit T
    J Med Assoc Thai; 2001 Apr; 84(4):500-6. PubMed ID: 11460960
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [On vaccination against measles with live and attenuated virus (Schwarz strain)].
    Monaci V; Imperato C; Battistini A; Nardi G; Grzincich GL; Bellelli E; Mazzeo G
    Ann Sclavo; 1973; 15(3):134-40. PubMed ID: 4776383
    [No Abstract]   [Full Text] [Related]  

  • 55. [Localization of specific antigen in the organs of animals inoculated with different series of live measles vaccine].
    Gorshunova LP; Maksimova-Todorova VA; Romanov VA; Vanag KA; Nabokova AV
    Biull Eksp Biol Med; 1978 May; 85(5):567-9. PubMed ID: 77691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accelerating measles control in India opportunity and obligation to act now.
    John TJ; Choudhury P
    Indian Pediatr; 2009 Nov; 46(11):939-43. PubMed ID: 19955577
    [No Abstract]   [Full Text] [Related]  

  • 57. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measles vaccination: new strategies and formulations.
    de Vries RD; Stittelaar KJ; Osterhaus AD; de Swart RL
    Expert Rev Vaccines; 2008 Oct; 7(8):1215-23. PubMed ID: 18844595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Two doses of measles vaccine: are some states in India ready for it?
    John S; Sanghi S; Prasad S; Bose A; George K
    J Trop Pediatr; 2009 Aug; 55(4):253-6. PubMed ID: 18799515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measles mortality reduction in Africa.
    Biellik RJ; Brown DW
    Lancet; 2009 Mar; 373(9668):984-5. PubMed ID: 19211139
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.